Objective: Our research was designed to evaluate the association of uncontrolled hypertension with coronary artery disease and analyze the role of intervention in preventing CAD mortality ratio. Methodology: This case controlled single-center study was conducted in the Department of Medicine, Peoples University of Medical and Health Sciences Nawabshah Pakistan from January 2020 to September 2021. In this study, BP screening was done among the adult population aged 50 years or over. All the recruited patients of coronary artery disease were divided into two main groups for a clinical trial; case (identified cases of uncontrolled hypertension) and the control group (without history of cardiovascular disorders and used medication for hypertension). For evaluating physician intervention, both groups were divided into two main groups for treatments; the standard Bp control.
(having <140 mm Hg SBP level) and the intensive blood pressure control (whose SBP <120 mm Hg), we used BP-lowering medication which adjusted the systolic blood pressure around 135–139 mm Hg in the standard group and less than 120 in intensive group.

**Results:** Overall the female prevalence was comparatively high (63.2%) than males (37%). No significant differences were found in the baseline characteristics of participants. In 42% of cases, we found coronary artery calcification. Univariate logistic analysis of our study demonstrates the association of CAD with age, smoking, and BMI. We also found a positive association of CAD with higher CRP, and uncontrolled hypertension.

**Conclusion:** Our study observed a significant association between uncontrolled hypertension and coronary artery disease. The results of our study concluded that interventions in terms of BP control might be affected due to pre-existing cardiovascular diseases. However, intensive BP treatment would help to reduce the mortality ratio of CAD patients.

**Keywords:** Uncontrolled blood pressure; coronary artery disease; Systolic blood pressure; intervention group; case controlled.

**1. INTRODUCTION**

Hypertension is one of the challenging issue of modern world which causes high prevalence of morbidity and mortality worldwide. Generally affecting more than one billion world population is affecting with hypertension including both developing and and developed countries. Overall 9.4 million hypertension related deaths were reported every year [1]. According to the medical 2025 becomes worsen year with 1.7 billion expected young deaths due to hypertension. In low-income countries, annually 6 million hypertensive deaths are reported every year [2]. Underdeveloped countries are the most easy target of hypertension disease due to unhygienic and poor diet plans with less awareness [3]. Currently 2/3rd hypertensive patients live in underdeveloped countries [3]. Disease burden of the poor countries increased due to high prevalence of hypertension. Usually, female population is more prone to the hypertension. Almost 6.8% female population suffered from cardiovascular diseases due to high prevalence of hypertension as compared to men (3.4%) [4]. In the past variety of researches were produced to demonstrate the association of elevated blood pressure with coronary artery disease (CAD) [1,2,3,4]. These results demonstrate that hypertension is the most prevalent disorder among 30% to 70% of individuals with pre-existing CAD [5]. A previous study reported an increased mortality ratio in patients aged 40-69 years after observing a 20mm Hg rise in systolic blood pressure and a 10 mm Hg rise in diastolic blood pressure (DBP) among patients with ischemic heart disease [6]. However, a reduction in SBP level may contribute to lowering the risk of deaths among cardiovascular patients [7]. Our research was designed to evaluate the association of uncontrolled hypertension with coronary artery disease and analyze the role of intervention in preventing CAD mortality ratio.

**2. METHODOLOGY**

This case controlled single-center study was conducted in department of Medicine, Peoples University of Medical and Health Sciences Nawabshah Pakistan from January 2020 to 2021. In this study, BP screening was done among the adult population aged 50 years or over. Before initiating the research, ethical approval was obtained from the hospital research ethics committee and research was conducted by following Helsinki principles. All the participants were well-known about the objectives and nature of the research. Written and verbal consent were obtained from every participant. Hypertensive patients were defined as those whose systolic blood pressure >140 mm Hg and >90 mm Hg with or without antihypertensive treatment. Patients who filled the written consent form were included for further observations. Patients aged 50 or above with an increased risk of cardiovascular events were included. We excluded all patients with a medical history of diabetes mellitus and chronic kidney disease. Furthermore, patients with prior stroke, myocardial infarction, congestive heart failure were also excluded from the research.

All the recruited patients of coronary artery disease were divided into two main groups for a clinical trial: case (identified cases of uncontrolled hypertension) and the control group (without history of cardiovascular disorders and used medication for hypertension). Trained physicians of the hospital to measure blood
pressure with standardized protocol by using automatic devices. Patients were asked to sit in a seated position for three BP measurements. All the BP measurements were 65 seconds apart. In the controlled group, we assured that the blood pressure of recruited participants ranges under 160/100. Coronary artery calcification (CAC) was identified by performing a CT scan of the case group. Agatston score was used to analyze CAC regression analysis. This score was then subdivided into five categories for analyzing low to severe coronary atherosclerosis. For evaluating physician intervention, both groups were divided into two main groups for treatments; the standard Bp control (having <140 mm Hg SBP level) and the intensive blood pressure control (whose SBP <120 mm Hg). We used ACE inhibitors (20 mg lisinopril tablet as BP-lowering medication) which adjusted the systolic blood pressure around 135–139 mm Hg in the standard group and less than 120 in intensive group. This tablet were given to patients after the 2 BP measurements and CT scan. Patients with a history of coronary artery bypass grafting and having a history of percutaneous coronary intervention were defined under the category of coronary revascularization. Primary outcomes of the research targeted composite events of myocardial infarction, heart failure, stroke, and cardiovascular death whereas events like hypotension, electrolyte abnormality, and bradycardia were also recorded. Patients were followed for 3 months for calculating mean SBP and DBP values. Demographic information including age, sex, smoking status of patients, body mass index, fasting plasma glucose levels, lipoprotein cholesterol, and triglycerides were recorded for statistical analysis [8,9].

We used SPSS 23.0 for statistical analysis. Mean and standard deviations were used for measuring continuous variables whereas Chi-square and student t-test was used for measuring categorical variables. For analysing the difference between two groups we used student t-test. Multivariate logistic regression with a 95% confidence interval for adjusted odds ratios was used to determine risk factors of hypertension associated with CAD.

3. RESULTS

This case-controlled trial study recruited 147 patients with hypertension. Among these patients, 49 had coronary artery disorder whereas the remaining ninety-eight were non CAD patients. Overall the female prevalence was comparatively high (63.2%) than males (37%). No significant differences were found in the baseline characteristics of participants (Table 1). CT scan was performed in the uncontrolled hypertensive group for coronary artery calcification. One of the patients had obesity so we failed to achieve CAC data of that patient. In 42% of cases, we found coronary artery calcification. Univariate logistic analysis of our study demonstrates the association of CAD with age, smoking, and BMI. We also found a positive association of CAD with higher CRP, and uncontrolled hypertension (Table 2). After a median follow-up of 6 months, we found that intensive BP treatment is highly associated with a low probability of mortality but enhances the risk of stroke. In patients, without CAD we found that intensive BP treatment decreased the risk of myocardial infarction, and heart failure than standard treatment (Table 4).

4. DISCUSSION

In this case-control study, we observed a significant association between uncontrolled hypertension and coronary artery disease. In our study, we found an increased prevalence of CT-detected coronary artery calcification. These results are in correspondence to the previous study of Allen [10] in which he observed a clear association of uncontrolled hypertension and coronary artery calcification. The significant results were found due to adjustment of cardiovascular risk factors including lipid parameters. The median CAC score and level of hypertension in the different categories of CAC in our study were comparable to the previous study of Heinz recall study [11]. Heinz’s study found similar parameters in stage 1-2 hypertension patients. We observed that CAC is an independent predictor of cardiovascular events as found in other studies [12,13,14]. But these results are in contradiction to the large cohort study in which they failed to analyze all clinical outcomes due to interventions that allow CAC screening [15]. The hypothesis claims that lipid-lowering therapy reduced the risk of cardiovascular events in hypertensive patients [16], however, our study was independent of lipid parameters.
Table 1. Demographic and clinical characteristics of recruited patients [9]

| Variables                              | Control group (General population) n=98 (66.6%) | Case group (uncontrolled hypertension) n= 49 (33.3%) | All subjects N= 147 | p-value |
|----------------------------------------|-----------------------------------------------|-----------------------------------------------------|---------------------|---------|
| Age                                    | 55±5                                          | 52±15                                               | 54±10               | 0.08    |
| Sex                                     |                                               |                                                     |                     | 1.0     |
| Male                                    | 36 (37%)                                      | 18 (37%)                                            | 54 (37%)            |         |
| Female                                  | 62 (63%)                                      | 31 (63.2%)                                          | 93 (63.2%)          |         |
| Diastolic blood pressure (mm Hg)       | 81±9                                          | 95±14                                               | 86±12               | <0.001  |
| Systolic blood pressure (mm Hg)        | 132±14                                        | 155±30                                              | 140±23              | <0.001  |
| Blood pressure ≥160/100 mm Hg          | 0                                             | 22 (45%)                                            | 22 (15%)            | <0.001  |
| Blood pressure >140/90 and <160/100 mm Hg | 34 (35%)                                      | 20 (41%)                                            | 54 (37%)            |         |
| Blood pressure <140/90 mm Hg           | 64 (65%)                                      | 7 (14%)                                             | 71 (48%)            |         |
| Antihypertensive treatment             | 24 (24%)                                      | 38 (83%)                                            | 62 (43%)            | <0.001  |
| No. of antihypertensive drugs          | 2 (1-4)                                       | 0                                                   | 0 (0–2)             | <0.001  |
| Body mass index (kg m⁻²)               | 28.5±4.7                                      | 28.8±4.9                                            | 28.6±4.7            | 0.2     |
| Triglycerides (mmol l⁻¹)               | 1.6±1.4                                       | 1.4±0.7                                             | 1.5±1.2             | 0.4     |
| Total cholesterol (mmol l⁻¹)           | 5.5±0.9                                       | 5.1±1.0                                             | 5.4±1.0             | 0.01    |
| HDL cholesterol (mmol l⁻¹) | 1.5±0.5 | 1.5±0.9 | 1.5±0.6 | 0.6 |
|---------------------------|---------|---------|---------|-----|
| LDL cholesterol (mmol l⁻¹) | 3.3±0.9 | 3.0±1.0 | 3.2±1.0 | 0.045 |
| Estimated GFR (ml min per 1.73 m²) | 89±18 | 78±18 | 85±19 | <0.001 |
| Creatinine (µmol l⁻¹) | 69±13 | 80±17 | 73±16 | <0.001 |
| C-reactive protein (mg l⁻¹) | 2.0 (0.9–4.0) | 2.5 (1.0–4.8) | 2.1 (1.0–4.0) | 0.2 |
| CAC score >399 U | 2 (2%) | 7 (14%) | 9 (6%) | 0.007 |
| CAC score >99 U | 11 (11%) | 14 (29%) | 25 (17%) | 0.008 |
| CAC score >9 U | 23 (24%) | 21 (43%) | 44 (30%) | 0.007 |
| CAC score >0 U | 37 (38%) | 25 (51%) | 62 (42%) | |
| CAC score = 0 U | 60 (62%) | 24 (49%) | 84 (58%) | 0.1 |
| Median CAC score (U) | 0 (0–9) | 4 (0–145) | 0 (0–38) | 0.04 |
| Active smoking | 22 (22%) | 11 (22%) | 33 (22%) | 1.0 |
Table 2. Multivariate logistic regression analysis for prediction of CAD [9]

| Risk Factors                  | Odd ratios  | p-value |
|-------------------------------|-------------|---------|
| Age (per year)                | 3.9 (1.6–9.1) | 0.002   |
| Uncontrolled hypertension     | 3.2 (1.2–8.5) | 0.02    |
| CRP (per mg l⁻¹)              | 1.08 (1.01–1.15) | 0.03     |
| Body mass index (per kg m⁻²)  | 1.11 (1.01–1.21) | 0.02     |

Table 3. Primary outcomes of intensive versus standard Bp treatment [8]

| Outcomes                   | Intensive BP treatment n= 25 | Standard BP treatment n= 24 | Adjusted Hazard ratio (95% C.I) | P value | Unadjusted Hazard ratio (95% C.I) | P value |
|----------------------------|-------------------------------|----------------------------|---------------------------------|---------|----------------------------------|---------|
| Primary outcome            | 12.9%                         | 12.0%                      | 1.05 (0.76–1.46)                | 0.87    | 1.04 (0.76–1.44)                 | 0.90    |
| All-cause death            | 5.0%                          | 7.7%                       | 0.60 (0.37–0.96)                | 0.03    | 0.62 (0.39–0.98)                 | 0.04    |
| CVD death                  | 2.1%                          | 2.6%                       | 0.75 (0.35–1.63)                | 0.47    | 0.77 (0.37–1.62)                 | 0.49    |
| Myocardial infarction      | 5.1%                          | 4.8%                       | 1.05 (0.62–1.75)                | 0.87    | 1.03 (0.62–1.72)                 | 0.90    |
| Stroke                     | 3.2%                          | 1.5%                       | 2.08 (0.94–4.58)                | 0.07    | 2.03 (0.93–4.46)                 | 0.08    |
| Heart failure              | 2.6%                          | 3.9%                       | 0.61 (0.32–1.17)                | 0.14    | 0.62 (0.33–1.18)                 | 0.15    |
| ACS                         | 3.4%                          | 2.7%                       | 1.22 (0.64–2.35)                | 0.55    | 1.20 (0.63–2.31)                 | 0.58    |

Table 4. Safety events of treatment [8]

| Safety events            | Intensive BP treatment | Standard BP treatment | Hazard ratio | p-value |
|--------------------------|------------------------|-----------------------|--------------|---------|
| Hypotension              | 4.8%                   | 2.4%                  | 2.00 (1.06–3.79) | 0.03    |
| Bradycardia              | 4.3%                   | 3.6%                  | 1.12 (0.63–1.98) | 0.71    |
| Syncope                  | 2.4%                   | 3.1%                  | 0.73 (0.37–1.47) | 0.38    |
| Acute kidney injury      | 6.1%                   | 4.3%                  | 1.39 (0.82–2.33) | 0.22    |
| Electrolyte abnormality  | 5.3%                   | 2.2%                  | 2.38 (1.25–4.56) | 0.01    |
| Serious adverse events   | 54.7%                  | 53.1%                 | 1.03 (0.88–1.20) | 0.73    |
| Injurious fall           | 3.1%                   | 2.4%                  | 1.21 (0.60–2.43) | 0.59    |

Our results also indicate that cardiovascular diseases highly affect the clinical outcomes of BP treatment. Intensive BP treatment reduced the risk of cardiovascular events in patients without CAD but failed to achieve any successful outcomes in CAD patients. However, intensive treatment reduced cardiovascular deaths in CAD patients without affecting any clinical outcomes. We observed a high probability of stroke in CAD patients during intensive BP treatment. The risk...
of stroke was also high in revascularization. However, in non-CAD hypertensive patients targeted systolic blood pressure 120 mm Hg reduced the clinical outcomes. The study of Attar et al. [17], observed successful outcomes of intensive BP treatment for primary prevention of cardiovascular disease and observed reduced mortality in high-risk CVD patients. In contradiction, the study of Sleight [18] found no outcome at < 130 SBP level.

In hypertensive cardiovascular patients, optimal BP targets remain controversial. A variety of studies related to CAD were produced in past but they ignored SBP targets. The international study conducted by Pepine et al. [19], suggested low SBP is more effective than antihypertensive drug class in patients aged 50 or above. Bangalore study suggested SBP below 140 mm Hg for better clinical outcomes in hypertensive CAD patients. On the other hand, the findings of network meta-analysis conducted in 2017 recommended SBP target be to <130 mm Hg in adults [20,21,22]. Usually, in CAD patients with hypertension, diastole causes coronary perfusion so DBP attain focus in recent years. One of the secondary analyses observed a J-shaped association between BP and cardiovascular events. They observed prominent J-curved in diastole than in systole. Many researchers reported a high potential of tolerating low levels of DBP in patients with coronary revascularization [23,24]. The other study suggested that a DPB level is lower than 70 mm Hg could be dangerous for patients with unstable angina [25]. Comparing these results of DBP with our study we observed that DBP around 65 mm Hg will be safe and did not increase CVD events.

Regardless of antihypertensive treatment, our study observed lower DBP levels in patients with a history of coronary revascularization. This happened due to poor arterial elasticity and atherosclerotic lesions in patients with revascularization. Loss of arterial elasticity leads to DBP decline and auto-regulatory process of the coronary circulation [26]. Regarding the cardiovascular risk factors including cholesterol, heart rate was better controlled in CAD than others.

5. CONCLUSION

Our study observed a significant association between uncontrolled hypertension and coronary artery disease. The results of our study concluded that interventions in terms of BP control might be affected due to pre-existing cardiovascular diseases. However, intensive BP treatment would help to reduce the mortality ratio of CAD patients.

6. LIMITATIONS OF THE STUDY

For this study we measured blood pressure with manually operated semi-automatic devices in control group which gave higher readings than the case group. This was the major limitation of study resulting in lower observed difference in both group. Due to this we observed a huge affect on systolic blood pressure in regression model. The percentage of hypertension patients with cardiovascular disorders was very small which affect our statistical analysis. Furthermore, we excluded patients with a history of diabetes mellitus or stroke, so our study conclusions may not apply to other subsets of patients. We recommend that further studies should be produced and carefully interpreted to validate these results.

CONSENT

As per international standard or university standard, patients' written consent has been collected and preserved by the author(s).

ETHICAL APPROVAL

As per international standard or university standard written ethical approval has been collected and preserved by the author(s).

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic, and cardiovascular risks. Us population data. Arch Intern Med. 1993;153:598–615.
2. Rapsomaniki E, Timmis A, George J, Pujades-Rodriguez M, Shah AD, Denaxas S, et al. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1.25 million people. Lancet. 2014;383:1899–911.
3. Forouzanfar MH, Liu P, Roth GA, Ng M, Biryukov S, Marczak L, et al. Global
burden of hypertension and systolic blood pressure of at least 110 to 115 mm Hg, 1990–2015. JAMA. 2017;317:165–82.

4. Lewington S, Lacey B, Clarke R, Guo Y, Kong XL, Yang L, et al. The burden of hypertension and associated risk for cardiovascular mortality in China. JAMA Intern Med. 2016;176:524–32.

5. Mahtta D, Elgendy IY, Pepine CJ. Optimal medical treatment of hypertension in patients with coronary artery disease. Expert Rev Cardiovasc Ther. 2018;16:815–23.

6. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903–13.

7. Oparil S, Acelajado MC, Bakris GL, Berlowitz DR, Cifkova R, Dominiczak AF, et al. Hypertension. Nat Rev Dis Prim. 2018;4:18014.

8. Zang J, Liang J, Zhuang X, et al. Intensive blood pressure treatment in coronary artery disease: implications from the Systolic Blood Pressure Intervention Trial (SPRINT). J Hum Hypertens; 2021.

9. Nielsen M, Pareek M, Gerke O, et al. Uncontrolled hypertension is associated with coronary artery calcification and electrocardiographic left ventricular hypertrophy: a case-control study. J Hum Hypertens. 2015;29:303–308.

10. Allen NB, Siddique J, Wilkins JT, Shay C, Lewis CE, Goff DC et al. Blood pressure trajectories in early adulthood and subclinical atherosclerosis in middle age. JAMA 2014;311(5):490–497.

11. Erbel R, Lehmann N, Möhlenkamp S, Churzidse S, Bauer M, Kälisch H et al. Subclinical coronary atherosclerosis predicts cardiovascular risk in different stages of hypertension: result of the Heinz Nixdorf Recall Study. Hypertension 2012; 59(1):44–53.

12. Detrano R, Guerci AD, Carr JJ, Bild DE, Burke G, Folsom AR et al. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. New Engl J Med 2008;358(13):1336–1345.

13. Polonsky TS, McClelland RL, Jorgensen NW, Bild DE, Burke GL, Guerci AD et al. Coronary artery calcium score and risk classification for coronary heart disease prediction. JAMA 2010; 303 (16): 1610–1616.

14. Erbel R, Möhlenkamp S, Moebus S, Schmermund A, Lehmann N, Stang A et al. Coronary risk stratification, discrimination, and reclassification improvement based on quantification of subclinical coronary atherosclerosis: the Heinz Nixdorf Recall study. J Am Coll Cardiol 2010; 56 (17): 1397–1406.

15. Bonow RO. Clinical practice. Should coronary calcium screening be used in cardiovascular prevention strategies? New Engl J Med 2009; 361 (10): 990–997.

16. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid-Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361 (9364): 1149–1158.

17. Attar A, Sayadi M, Jannati M. Effect of intensive blood pressure lowering on cardiovascular outcomes based on cardiovascular risk: a secondary analysis of the SPRINT trial. Eur J Prev Cardiol. 2019;26:238–45.

18. Sleight P, Redon J, Verdecchia P, Mancia G, Gao P, Fagard R, et al. Prognostic value of blood pressure in patients with high vascular risk in the ongoing telmisartan alone and in combination with ramipril global endpoint trial study. J Hypertens. 2009;27:1360–9.

19. Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The international verapamil-trandolapril study (INVEST): a randomized controlled trial. JAMA. 2003;290:2805–16.

20. Pepine CJ. What is the optimal blood pressure and drug therapy for patients with coronary artery disease? JAMA. 2004;292:2271–3.

21. Welton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/ABC/ACP/AAPA/AGS/APHA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. Hypertension. 2018;71:e13–e115.
22. SPRINT Research Group, Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, et al. A randomized trial of intensive versus standard blood-pressure control. N. Engl J Med. 2015;373:2103–16.

23. Bundy JD, Li C, Stuchlik P, Bu X, Kelly TN, Mills KT, et al. Systolic blood pressure reduction and risk of cardiovascular disease and mortality: a systematic review and network meta-analysis. JAMA Cardiol. 2017;2:775–81

24. Messerli FH, Mancia G, Conti CR, Hewkin AC, Kupfer S, Champion A, et al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med. 2006;144:884–93.

25. Witteman JC, Grobbee DE, Valkenburg HA, van Hemert AM, Stijnen T, Burger H, et al. J-shaped relation between change in diastolic blood pressure and progression of aortic atherosclerosis. Lancet. 1994;343:504–7.

26. Casadonte L, Verhoeff BJ, Piek JJ, VanBavel E, Spaan JAE, Siebes M. Influence of increased heart rate and aortic pressure on resting indices of functional coronary stenosis severity. Basic Res Cardiol. 2017;112:61.

© 2021 Memon et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited

Peer-review history:
The peer review history for this paper can be accessed here:
https://www.sdiarticle5.com/review-history/78323